Affordable Access

Canrenone--the principal active metabolite of spironolactone?

Authors
  • Ramsay, L E
  • Shelton, J R
  • Wilkinson, D
  • Tidd, M J
Type
Published Article
Journal
British journal of clinical pharmacology
Publication Date
Aug 01, 1976
Volume
3
Issue
4
Pages
607–612
Identifiers
PMID: 22216502
Source
Medline
License
Unknown

Abstract

The properties of the aldosterone antagonists spironolactone and potassium canrenoate in tablet formulations were examined in two studies in healthy subjects, the first study comparing levels of their common major metabolite, canrenone, in plasma and the second study comparing the pharmacological activity of the two drugs in reversing the renal effects of the synthetic mineralocorticoid fludrocortisone. At equal dosage by weight potassium canrenoate yielded peak levels and areas under the curve for canrenone in plasma which were significantly lower than those for spironolactone, and the peak level of canrenone was reached significantly later. Comparison with published work suggests that the experimental formulation of potassium canrenoate had low bioavailability. Spironolactone produced statistically valid log dose-response curves against fludrocortisone as regards sodium excretion, potassium retention and increased urine sodium to potassium ratio. There was no significant log dose-reponse after potassium canrenoate, and a statistically valid estimate of relative potency could not be obtained. The results of the two studies seem inconsistent with the view that canrenone alone is responsible for the pharmacological activity of both drugs, and suggest that a significant part of the activity of spironolactone may be attributable to metabolites other than canrenone.

Report this publication

Statistics

Seen <100 times